Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
about
The Role of Serine Proteases and Antiproteases in the Cystic Fibrosis LungThe I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation.Host-pathogen interplay in the respiratory environment of cystic fibrosis.Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosisNew insights into pulmonary inflammation in cystic fibrosis.Neutrophil serine proteases fine-tune the inflammatory responseSputum biomarkers of inflammation in cystic fibrosis lung diseaseProteases and cystic fibrosis.Advances in neutrophil biology: clinical implications.Intracellular and extracellular serpins modulate lung disease.Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosisAlpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent.Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises.Emerging drugs for cystic fibrosis.The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 - 2015).Antiproteases as therapeutics to target inflammation in cystic fibrosis.The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity.Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes.Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum.Stability and activity in sputum of G10KHc, a potent anti-Pseudomonas antimicrobial peptide.The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency.Novel therapeutic uses of alpha-1 antitrypsin: a window to the future.Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment.The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals.Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement
P2860
Q26799771-FF7070AC-5516-42D2-A0A7-BC6895ADA8A0Q33550523-D64F4BCB-6072-4ADC-B4F3-5C2B25065550Q33799602-9B335A7C-9508-4BD5-8DEF-F512603973DEQ35799736-2AB2F7AD-5708-4B18-8D37-F65569876DCCQ36488777-38641D17-A4E6-46C3-8551-E08A67B40374Q36573117-4A4527A6-B8C0-450B-B698-C09CC68C96E9Q36737987-463BF70F-C2DA-4EC6-AE4C-FF97899206C1Q36891552-7AEF56F0-3FD8-48F7-9DB2-004E79006C4CQ37131650-E14664A1-EC1B-467B-8811-07570EA2922AQ37263668-488EB47F-0FF3-4E94-8227-CE3B0A3CA5C9Q37341652-4E8EE3AF-5200-42CC-A495-9897104E0353Q37819431-A5656523-7AD0-4C61-A471-BD9E4417F1CDQ37986292-70093737-DB12-49F1-AF73-708825F975DDQ38033610-B487B4DF-F774-40B2-95A6-4A15EC0BB19BQ38183476-01E3EE4E-89FC-4961-B291-A520F1CD10A7Q38322575-0FBE3F83-B0DC-4221-BFC4-387ED011A356Q38769762-4745196A-3B9A-4E98-A027-745E02FEAEB1Q40363808-A93931D8-5901-4E57-B24D-49A476A74247Q42234561-001202F5-6BB0-4534-B35D-7CDA24505DCEQ42590837-4DD3C592-B246-4595-ACC2-6EBFEE7B1E07Q45133825-482DB778-88FB-42E2-AD66-D7925365703EQ46619725-98E9EA68-E7EF-4C71-AC40-EA9CBBA52E70Q51465407-F8946837-5191-429B-9BFA-124B4BE73FCEQ51534901-3E7B780A-A4DB-43F2-8089-6F6079D760F9Q51568269-7AFBAF86-8043-405D-9019-7899999383D5Q55011363-88A7C5AE-831C-4C64-A07B-0CBE20AB6F4BQ58580727-58F78D3C-FD97-4647-9D43-3F8F733044BC
P2860
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Safety and efficacy of recombinant alpha
@nl
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
@en
type
label
Safety and efficacy of recombinant alpha
@nl
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
@en
prefLabel
Safety and efficacy of recombinant alpha
@nl
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
@en
P2093
P356
P1476
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
@en
P2093
Diana Bilton
Julia Edgar
Mary T Keogan
Recombinant AAT CF Study Team
S Lorraine Martin
P304
P356
10.1002/PPUL.20345
P577
2006-02-01T00:00:00Z